Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 3Tumor-Agnostic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6Nivolumab 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Rosuvastatin Calcium × Endocrine × Clear all
NCT04889287 2023-08-09

A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants

Bayer

Phase 1 Completed
16 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡